- BiondVax Pharmaceuticals Ltd. (BVXV): Important & Key Factors of Healthcare Stock
- What's the Analyst Recommendation for iHeartMedia Inc. (IHRT)?
- Let’s Take a Look at Milestone Pharmaceuticals Inc. (MIST) Stock
- Is it Time to Sell/Buy United States Steel Corporation (X) Stock After Recent Trade?
- Aptose Biosciences Inc. (APTO) is down -10.05% this year
Jaguar Health, Inc. (NASDAQ:JAGX) recently reported that the company’s wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), has commence its pivotal Phase 3 clinical trial of crofelemer (Mytesi®) for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy (“cancer therapy‑related diarrhea” (CTD)).
The Phase 3 pivotal clinical trial is a 24-week (two 12-week stages), randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of crofelemer (Mytesi) in providing prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted cancer therapy-containing treatment regimens. Crofelemer or placebo treatment will start concurrently with the targeted cancer therapy regimen. The primary endpoint will be assessed at the end of the initial (Stage I) 12-week double-blind placebo-controlled primary treatment phase. After completing the Stage I treatment phase, the subjects will have the option to remain on their assigned treatment arm and reconsent to enter into the Stage II 12-week extension phase. The safety and efficacy of orally administered crofelemer will be evaluated for the prophylaxis of diarrhea in adult cancer patients receiving targeted cancer therapies with or without standard chemotherapy regimens. The assessment of the frequency of diarrhea will be measured by the number of loose and/or watery stools for the Stage I treatment period. Additional details about the trial can be viewed on the clinicaltrials.gov website. The National Clinical Trial number for the trial is NCT04538625.
According to the Centers for Disease Control and Prevention (CDC), approximately 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic each year. A significant proportion of patients undergoing cancer therapy experience diarrhea, and diarrhea has the potential to cause dehydration, potential infections, and non-adherence to treatment in this population.
Jaguar Health Inc. (JAGX) share price soaring 0.61% with the price of $0.33 at the time of writing this article. Jaguar Health Inc. stock has an exchanging volume of 1,375,242 shares. Its market capitalization has now reached to $16.04M.
JAGX Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, JAGX price has rose by 10.44%. In the course of past three months sees the stock go down around -41.50%, while it has lost -30.95% over the past six months and -59.05% since the start of the year.
JAGX Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 3.17 billion, which was higher than the gauge of 5.82M made by certain experts. For that equivalent quarter, Jaguar Health Inc. posted -$0.29 earnings per share (EPS) which was underneath the consensus estimate of -$0.15 by -$0.14, which represents to a reduction by -93.30%.
JAGX Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Jaguar Health Inc. has seen its stock exchanging -61.36% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +15.53% above its three-month low. A more extensive look sees JAGX exchanging -73.11% beneath its 52-week high and 15.53% above from its 52-week low price.
JAGX Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 11.93%, while it has a month to month instability of 11.60%. The company has an ATR (Average True Range) of 0.04 and a beta factor of 0.78.